English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduHead and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth.
Tag: Clinical Trial
Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI),…
BIDMC-led trial leads to FDA approval of coronary drug-coated balloons
In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.
This Injectable Hydrogel Mitigates Damage to the Right Ventricle of the Heart
An injectable hydrogel can mitigate damage to the right ventricle of the heart with chronic pressure overload, according to a new study published March 6 in Journals of the American College of Cardiology: Basic to Translational Science. The study, by a research team from the University of California San Diego, Georgia Institute of Technology and Emory University, was conducted in rodents.
HIV Medication Can be Used Safely with Gender-Affirming Hormone Therapy
New research shows HIV medications can be taken at the same time as hormone treatment without losing potency of either therapy.
L-Nutra Unveils Groundbreaking Research on Fasting Mimicking Diets (FMDs) and Reduced Biological Age Score
L-Nutra Inc., a leading nutrition technology company developing evidence-based Nutrition for Longevity and Nutrition as Medicine programs, is excited to announce the release of a groundbreaking longevity and healthy aging study published in Nature Communications, a prestigious Nature portfolio journal.
Clinical trial tests combination antibody therapy in adults with advanced cancer
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.
First Drug to Help Reduce Allergic Reactions to Multiple Food Allergies, Tested at Children’s and Emory, Now FDA Approved
Children’s Healthcare of Atlanta and Emory University participated in a nationwide clinical trial showing that a 16-week course of omalizumab, an injectable drug, increased the amount of peanut, tree nuts, egg, milk and wheat that some multi-food allergic children as young as one year could consume without an allergic reaction after exposure.
Research Study on Novel Rehab Program for Heart Failure Patients, Led by Wake Forest University School of Medicine, Expands to Advocate Health Site in Chicago
Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding another research study to Advocate Christ Medical Center, in Oak Lawn, Illinois, just outside Chicago.
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant, awarded to Wake Forest University School of Medicine in 2022 by the National Institute on Aging, part of the National Institutes of Health.
Mount Sinai Receives $2.6 Million Grant From PolyBio Research Foundation for Long COVID Clinical Trials
Funding will also support researching other complex illnesses and medical education
Intravascular Imaging Significantly Improves Survival, Safety, and Outcomes in Cardiovascular Stenting Procedures Over Conventional Angiography
Results from this large-scale synthesis of all prior clinical trials could increase usage of several types of high-resolution imaging for guiding interventional coronary procedures
New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
Dementia Researchers Share Recruitment Strategies for Pragmatic Clinical Trial
The Dementia Care (D-CARE) Study (2019-2023), which was conducted at four clinical trial sites in the U.S., compared three approaches in dementia care. Despite challenges during the COVID-19 pandemic, D-CARE successfully enrolled 2,176 racially/ethnically diverse persons with Alzheimer’s disease or related dementias and their caregivers.
CSOFT Health Sciences Releases MDR White Paper to Support EU Medical Device Compliance
CSOFT Health Sciences, leaders in clinical trial translation, are pleased to announce the launch of their co-authored white paper for medical device manufacturers seeking re-certification under the updated EU Medical Device Regulation (EU MDR), in collaboration with partner organizations Gouya Insights and GCP-Service International Ltd. & Co.KG to jointly offer manufacturers an end-to-end platform for establishing conformity with policies set to take effect by January 2028.
Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial finds
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors
Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
Clinical trial demonstrates benefits of solriamfetol for adults with ADHD
Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use.
Breast Cancer at 30?
Amanda Butler and Isabella Bugatti, both just entering their 30s, were blindsided by a diagnosis that is on the rise among women their age: breast cancer.
High-dose radiation offers new treatment option for older patients with inoperable kidney tumors
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests.
Five Questions Parents Should Ask Their Child’s Oncologist About Participating in a Clinical Trial
When children undergo cancer treatment, they may be offered the chance to participate in a clinical trial. Clinical trials can provide access to new, groundbreaking therapies in a safe and controlled environment.
Ohio State first in world to participate in trial of device designed to alleviate heart failure symptoms
The Ohio State University Wexner Medical Center on Wednesday randomized the first patient in the world in a clinical trial evaluating the effectiveness of a device designed to alleviate heart failure symptoms.
Adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer
New study results indicate that combining two separately promising therapies for radioiodine-resistant thyroid cancer does not bring any added benefit.
UC Davis Eye Center tests experimental gene therapy for wet age-related macular degeneration (AMD)
Ophthalmologists at UC Davis Health used an experimental gene therapy last month to treat a patient with wet age-related macular degeneration, or wet AMD. Wet AMD is a leading cause of vision loss among older adults. Glenn Yiu, a professor of ophthalmology at UC Davis Health, is the principal investigator for the new clinical trial.
Optical Coherence Tomography May Improve Safety and Outcomes for Stenting Procedures in Heart Disease Patients Compared to Conventional Angiography
Results from a large-scale clinical trial results could increase usage of high resolution imaging for guiding interventional coronary procedures
Small Percentage of People with Early Dementia Eligible for New Alzheimer’s Drugs
Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Study finds improved survival for incurable brain tumor, providing ‘a crack in the armor’
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG), compared to previous patients.
Mount Sinai Receives Significant Funding to Study Which Coronary Revascularization Procedure Best Improves Survival and Quality of Life for Women and Underserved Minority Groups
The Icahn School of Medicine at Mount Sinai will help lead and launch the first clinical trial focusing on women and minority populations to determine which coronary revascularization procedure best improves their survival and quality of life.
One-Two Punch: Novel Drug Pairing Could Beat Pancreatic Cancer
UC San Diego researchers find a combination of drugs outperformed other treatments in human and mouse models of pancreatic cancer; now urge clinical trial.
Breakthrough in Glioblastoma Treatment with the Help of a Virus
Howard Colman, MD, PhD, was recently featured as an author on a publication in Nature Medicine describing the results of a recent clinical trial – a breakthrough in glioblastoma treatment with the help of a modified cold virus injected directly into the tumor. When combined with an immunotherapy drug, the authors observed a subset of patients that appeared to be living longer as a result of this therapy.
Osimertinib shows promising phase-3 results for non-small cell lung cancer
Researchers at Yale School of Medicine have presented findings from an international late-stage clinical trial that shows the targeted therapy osimertinib improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer following surgery. The…
Eye drops slow nearsightedness progression in kids, study finds
The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon.
UTHealth Houston awarded nearly $13M in grants to study treatments for traumatic brain injury
Nearly $13 million in federal grant funds to study treatments for traumatic brain injury, which kills an average of 190 people and hospitalizes another 600 in the U.S. every day, has been awarded to UTHealth Houston by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP).
Drug significantly reduces chorea symptoms in patients with Huntington’s disease
The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington’s disease, when compared to a placebo, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.
AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023. The studies, which describe results from a novel FGFR inhibitor and from new PARP/ATR inhibitor combinations, were featured in a plenary session highlighting novel biomarker-driven molecularly targeted therapy trials.
IU cancer center researcher leads first in-human multiple myeloma study with 90.5 percent response rate
Indiana University Melvin and Bren Simon Comprehensive Cancer Center served as the lead site for a promising first-in-human clinical trial for patients with relapsed multiple myeloma. Patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5 percent overall response rate.
Leaps in artificial blood research aim to improve product safety, efficacy
Researchers have made huge strides in ensuring that red blood cell substitutes – or artificial blood – are able to work safely and effectively when transfused into the bloodstream.
AACR: YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.
Rutgers Launches Lyme Disease Vaccine Study
The university is participating in the effort to determine the efficacy of what could be the first vaccine to prevent Lyme disease in children ages 5 to 17
Prestigious New England Journal of Medicine Publishes Ochsner Health’s Research into Alternative to Amputation
Ochsner Health is one of 20 sites in the U.S. participating in the PROMISE II clinical trial, which was recently published in the New England Journal of Medicine.
Chula Makes Progress in “CAR T-Cell Therapy” Innovation: New Hope for Thai Lymphoma Cancer Patients
Chulalongkorn University, Thailand, and Nagoya University, Japan, in their collaboration to develop an immunotherapy method for curing cancer, reported on the progress of CAR T-cell immunotherapy innovation for treating cancer in leukemia and B-cell lymphoma patients, which can increase survival rates and reduce cancer recurrence.
Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma
In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children’s Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma.
University Hospitals Research Published in New England Journal of Medicine Shows Minimally Invasive Procedure Saves Most Patients with Severe Vascular Disease from Amputation
A study, co-led by University Hospitals Harrington Heart & Vascular Institute, could lead to the first FDA approval of a therapy giving thousands of patients hope for an alternative to amputation.
TWO CLINICAL TRIALS REVEAL ADDITION OF IMMUNOTHERAPY TO CHEMOTHERAPY REGIMEN INCREASES PROGRESSION-FREE SURVIVAL IN ENDOMETRIAL CANCER PATIENTS
The results of two clinical trials, presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showcased adding immunotherapy to standard chemotherapy resulted in significantly longer progression-free survival (PFS) among patients with advanced or recurrent endometrial cancer (EC).
TRIAL’S LONG-TERM FOLLOW-UP DATA SHOWS NO DIFFERENCE IN OVERALL SURVIVAL AMONG OVARIAN CANCER PATIENTS WHO DID AND DID NOT RECEIVE PARP INHIBITOR MAINTENANCE THERAPY
After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.
CLINICAL TRIAL PARTICIPATION ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN OVARIAN CANCER PATIENTS
Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
STUDY FINDS INTRIGUING OUTCOMES IN OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS BEFORE SURGICAL INTERVENTION AND SUBSEQUENT CHEMOTHERAPY
Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Immunotherapy After Surgery Provides Significant, Durable Benefit for High-Risk Bladder Patients
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Genitourinary Cancers Symposium in February.
LAPD Sergeant Didn’t Walk Alone
Every day for six weeks, Neil Wank, a 26-year Los Angeles Police Department veteran who in December was diagnosed with an aggressive type of brain cancer called glioblastoma, was escorted down the long hallway leading to the Cedars-Sinai Cancer radiation therapy facility by his wife, Nikki, and 10 to 20 of his fellow officers.
Falling PSA levels predict longer survival in prostate cancer patients at high risk of metastases
Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
New Formulation of FDA-Approved Drug Shows Encouraging Results for Treating a Common Itch Condition
Notalgia paresthetica is a common and underdiagnosed condition characterized by a persistent itch in the upper back. To date, there are no FDA-approved treatments specifically targeting this disorder. But a new study, published in the NEJM, suggests that patients with the disorder could potentially get relief with oral difelikefalin.